ARMPNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Armata Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$3.07−0.30 (-8.90%)
Close on Oct 19, 2026
- Market cap
- $190.47M
- P/E (TTM)
- –
- Dividend yield
- –
Armata Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Armata Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $114.15M | $166.30M |
| Enterprise Value | $90.20M | $88.19M |
Income (trailing twelve months)
| Measure | Armata Pharmaceuticals | Industry median |
|---|---|---|
| Operating Income | -$40.70M | -$21.40M |
| Net Income | -$192.18M | -$22.46M |
| EBITDA | -$40.70M | -$16.91M |
| EPS (Diluted) | -$7.59 | -$0.83 |
Returns
| Measure | Armata Pharmaceuticals | Industry median |
|---|---|---|
| Return on Assets (ROA) | -225.1% | -40.9% |
Balance sheet
| Measure | Armata Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $23.95M | $61.43M |
| Net Cash (Debt) | $23.95M | $15.35M |
| Net Cash Per Share | $0.64 | $0.66 |
| Equity (Book Value) | -$231.17M | $49.09M |
| Book Value Per Share | -$6.22 | $1.37 |
| Tangible Book Value | -$244.92M | $23.52M |
| Working Capital | -$223.04M | $76.81M |
Financial position
| Measure | Armata Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 0.11 | 3.34 |
| Quick Ratio | 0.10 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Armata Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$25.42M | -$12.35M |
| Capital Expenditures | -$374.00K | -$1.08M |
| Free Cash Flow | -$25.79M | -$20.22M |
| FCF Per Share | -$0.69 | -$0.42 |
Efficiency
| Measure | Armata Pharmaceuticals | Industry median |
|---|---|---|
| Profits Per Employee | -$3.15M | -$703.34K |
| Employee Count | 61 | 74 |
Dividends and yields
| Measure | Armata Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -168.4% | -23.3% |
| FCF Yield | -22.6% | -8.72% |
Shares
| Measure | Armata Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 37,182,000 | 58,127,000 |
| Shares Change (YoY) | 1.85% | 10.9% |
| Shares Held by Institutions | 13.4% | 59.4% |
Scores
| Measure | Armata Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -12.70 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Armata Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.